Felix Y. Feng, M.D.
Vice Chair for Faculty Development
and Translational Research,
Department of Radiation Oncology
Associate Professor of Radiation Oncology,
Dr. Felix Feng is a radiation oncology leader in translational research. The primary aim of Dr. Feng’s research program is to individualize therapy for patients with aggressive prostate cancer, by identifying determinants of treatment resistance and developing strategies to overcome this resistance.
To enhance current clinical approaches from a biological perspective, his laboratory and dedicated research team are pursuing three major goals: 1) to identify novel molecular biomarkers of aggressive prostate cancer, 2) to understand the mechanisms by which several of these biomarkers drive disease progression, and 3) to develop therapeutic approaches to target these disease drivers.
Dr. Feng serves on the National Cancer Institute Genitourinary Cancer Steering Committee, which oversees and evaluates clinical trials proposed by all national clinical trials cooperative groups. He also serves as Chair of the Biology Scientific Track for the American Society of Radiation Oncology, and as Chair of the Genitourinary Translational Research Program for the RTOG/NRG national cooperative group.
|1994-1998||Stanford University||BS||Distinction and Honors in Biological Sciences|
|1998-2002||Washington University School of Medicine||MD|
|2002-2003||Saint Joseph Mercy Hospital, Ypsilanti, Michigan||Internship||Internal Medicine|
|2003-2005||University of Michigan Medical Center, Ann Arbor, Department of Radiology||Resident||Radiology|
|2005-2006||University of Michigan Medical Center, Ann Arbor, Department of Radiation Oncology||Postdoctoral Research Fellow||Radiation Biology|
|2006-2010||University of Michigan Medical Center, Ann Arbor, Department of Radiation Oncology||Resident||Radiation Oncology|
|2009-2010||University of Michigan Medical Center, Ann Arbor, Department of Radiation Oncology||Chief Resident||Radiation Oncology|
|PRINCIPAL POSITIONS HELD|
|2013-2016||University of Michigan, Ann Arbor||Director, Division of Translational Genomics||Radiation Oncology|
|2010-2016||University of Michigan, Ann Arbor||Assistant Professor||Radiation Oncology|
|2016-present||University of California, San Francisco||Vice Chair for Faculty Development and Translational Research||Radiation Oncology|
|2016-present||University of California, San Francisco||Associate Professor of Radiation Oncology, Urology, and Medicine||Radiation Oncology and Urology|
|OTHER POSITIONS HELD CONCURRENTLY|
|2010-2016||The University of Michigan Comprehensive Cancer Center Primary: Prostate Cancer Program Secondary: Radiation Sciences||Core Member||Radiation Oncology|
|2010-2016||Ann Arbor Veteran's Health System, Ann Arbor, Michigan||Assistant Professor||Radiation Oncology|
|2011-2011||Ann Arbor Veteran's Health System, Ann Arbor, Michigan||Acting Chief||Radiation Oncology|
|2011-2016||University of Michigan||Chair||Genitourinary Translational Research Program for the NRG/RTOG Cooperative Trials Group|
|2011-2016||Allegiance Health System, Jackson, Michigan||Active Staff||Radiation Oncology|
|2011-2016||Ingham Regional Medical Center, Lansing, Michigan||Active Staff||Radiation Oncology|
|2011-2016||Providence Hospital, Southfield, Michigan||Active Staff||Radiation Oncology|
|2015-2016||University of Michigan, Ann Arbor||Associate Chair for Laboratory Research||Radiation Oncology|
|2010-present||NRG/RTOG Cooperative Group||Leader||Genitourinary Cancer Translational Research Program|
Awards & Honors
|1994||President's Scholar for Academic Achievement (for scholastic achievement at Stanford University)|
|1995||President's Award for Academic Excellence (for scholastic achievement at Stanford University)|
|1997||Barry M. Goldwater Fellowship for Excellence in Mathematics, Science, and Engineering (national collegiate award/grant for outstanding basic science research)|
|1998||Dr. Philip Majerus Distinguished Alumni Scholarship 1998-2002 (full-tuition, four-year merit scholarship at the Washington University School of Medicine, awarded to three students per class)|
|1999||Washington University Research Award (best summer research project among med students)|
|2000||American College of Physicians Award for Excellence in Physical Diagnosis|
|2000||Best Presentation, Midwest Association of Plastic Surgeons Conference|
|2000||McLaughlin Award, National Student Research Forum (for best presentation in immunology)|
|2002||Dr. Richard S. Brookings Medical School Prize (awarded for the highest achievement in research among the graduating medical school class)|
|2002||Missouri State Medical Association Award (for scholastic achievement in medical studies)|
|2006||Merit award, Translational Research Symposium, ASTRO|
|2006||First place presentation, Michigan Society of Therapeutic Radiation Oncology (MSTRO) Resident Research Competition|
|2008||ASTRO Resident Clinical Research Award (for the best abstract submitted by a resident physician to the annual meeting)|
|2009||Travel grant, Radiation Therapy Oncology Group annual meeting|
|2009||Resident Scholarship for American Brachytherapy Society/Seattle Prostate Brachytherapy course|
|2010||Radiological Society of North America Roentgen Resident/Fellow Research Award|
|2012||American Society of Radiation Oncology Basic Science Award (for the best basic science abstract submitted to the annual meeting of this group)|
|2014||Teacher of the Year, Radiobiology, Department of Radiation Oncology, University of Michigan|
|2016||American Society of Radiation Oncology Clinical Science Award (for the best clinical science abstract submitted to the annual meeting of this group)|
Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, Schiewer MJ, Spratt DE, Kothari V, Klein EA, Den RB, Dicker AP, Karnes RJ, Yu X, Nguyen PL, Rubin MA, de Bono J, Knudsen KE, Davicioni E, Feng FY. JAMA Oncol. 2016 Jan 7:1-10. PMID: 26746117
DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. Goodwin JF, Kothari V, Drake JM, Zhao S, Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Jones JK, Aytes A, Magee MS, Snook AE, Zhu Z, Den RB, Birbe RC, Gomella LG, Graham NA, Vashisht AA, Wohlschlegel JA, Graeber TG, Karnes RJ, Takhar M, Davicioni E, Tomlins SA, Abate-Shen C, Sharifi N, Witte ON, Feng FY, Knudsen KE. Cancer Cell. 2015 Jul 13;28(1):97-113. PMID: 26175416
Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. Muralidhar V, Chen MH, Reznor G, Moran BJ, Braccioforte MH, Beard CJ, Feng FY, Hoffman KE, Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Int J Radiat Oncol Biol Phys. 2015;93(4):828-35. doi: 10.1016/j.ijrobp.2015.07.2281. PubMed PMID: 26530751.
Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB,Feng FY. Eur Urol. 2015 Oct;68(4):555-67. PMID: 25964175
The landscape of long noncoding RNAs in the human transcriptome. Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, Poliakov A, Cao X, Dhanasekaran SM, Wu YM, Robinson DR, Beer DG, Feng FY, Iyer HK, Chinnaiyan AM. Nature Genetics. 2015 Mar;47(3):199-208.
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM. Nature. 2014;510(7504):278-82.
A Tissue Biomarker-Based Model That Identifies Patients with a High Risk of Distant Metastasis and Differential Survival by Length of Androgen Deprivation Therapy in RTOG Protocol 92-02. Pollack A, Dignam JJ, Diaz DA, Wu Q, Stoyanova R, Bae K, Dicker AP, Sandler H, Hanks GE, Feng FY. Clin Cancer Research. 2014 Dec 15;20(24):6379-88.
RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, Klein EA, Jenkins RB, Chinnaiyan AM, Feng FY. Lancet Oncol. 2014 Dec;15(13):1469-80. PMID:25456366
The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc. Prensner JR, Chen W, Han S, Iyer MK, Cao Q, Kothari V, Evans JR, Knudsen KE, Paulsen MT, Ljungman M, Lawrence TS, Chinnaiyan AM, Feng FY. Neoplasia. 2014 Nov 20;16(11):900-8.
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY. Cancer Res. 2014 Mar 15;74(6):1651-60. PMID: 24473064